Oh, and I forgot an obvious prediction: that there will be many fewer approvals for Follow On Indications. For many drugs this doesn’t matter much, but for some it’s a huge factor. Oncology, TNF drugs, CD19 targeting drugs, … .
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.